Prevalence of polycythemia vera and essential thrombocythemia.
paper
Cited
Public
Unavailable
- Authors
- Ma, Xiaomei; Vanasse, Gary; Cartmel, Brenda; Wang, Yun; Selinger, H Andrew
- Year
- 2008
- Journal
- American journal of hematology
- PMID
- 18181200
- DOI
- 10.1002/ajh.21129
Polycythemia vera (PV) and essential thrombocythemia (ET) are common types of myeloproliferative disorders (MPD), the prevalence of which has not been well documented in the United States. Recent breakthroughs in the molecular etiology of these disorders and the accelerated development of targeted pharmacotherapeutics to treat them underscore the need to define the affected population. In this study, we obtained health claims data from major commercial insurance payers in Connecticut and the Center for Medicare and Medicaid Services to estimate the prevalence of PV and ET. Specifically, logistic regression was utilized to develop algorithms to predict the probability that an individual with claims suggestive of MPD truly has PV or ET, and the algorithms were then applied to health claims to estimate the number of PV and ET patients in Connecticut. As of 2003, the age-standardized prevalence was 22 per 100,000 and 24 per 100,000 for PV and ET, respectively, in Connecticut. Applying the age-specific prevalence of PV and ET to the entire US population resulted in an estimated total of 65,243 patients with PV and 71,078 patients with ET in the United States in 2003. This study is the first to assess the prevalence of PV and ET in a large US population. Given the large number of individuals afflicted with these diseases and the fact that demographic changes alone will further increase the burden of
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| Detectable clonal mosaicism from birth to old age and its relationship to cancer. | 2012 | 22561516 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Characterization of primary and secondary polycythemia among Palestinian blood donors in the West bank. | Odeh G et al. | β | 2025 | β |
| Population Pharmacokinetics-Pharmacodynamics and Exposure-Response of Ropeginterferon Alfa-2b in Chinese and Japanese Patients With Polycythemia Vera. | Qin A et al. | β | 2025 | β |
| Real-world characteristics and treatment patterns in essential thrombocythemia: a population-based cross-sectional study in Taiwan between 2020 and 2021. | Yu MS et al. | β | 2025 | β |
| Brain perfusion changes in beta-thalassemia. | Manara R et al. | β | 2024 | β |
| Clinical and Economic Implications of Hydroxyurea Intolerance in Polycythemia Vera in Routine Clinical Practice. | Ellis MH et al. | β | 2024 | β |
| C-Mannosyl tryptophan is a novel biomarker for thrombocytosis of myeloproliferative neoplasms. | Tabata S et al. | β | 2024 | β |
| Exposure-efficacy and exposure-safety analyses of ropeginterferon alfa-2b treatment in patients with polycythaemia vera. | Qin A et al. | β | 2024 | β |
| Aspirin in essential thrombocythemia. For whom? What formulation? What regimen? | Cattaneo M | β | 2023 | β |
| General anesthesia with nerve blocks for a patient with femoral fracture and essential thrombocythemia: a case report. | Su M et al. | β | 2023 | β |
| Polycythemia Vera: Barriers to and Strategies for Optimal Management. | Duminuco A et al. | β | 2023 | β |
| Polycythemia with elevated erythropoietin production in a patient with a urinary stone and unilateral hydronephrosis: a case report. | Hajika Y et al. | β | 2023 | β |
| Real-world patient characteristics and treatment patterns of polycythemia vera in Taiwan between 2016 and 2017: a nationwide cross-sectional study. | Tsai TH et al. | β | 2023 | β |
| Toe Gangrene as the First Presenting Symptom of Essential Thrombocythemia: A Case Report. | Altayyan MM et al. | β | 2023 | β |
| Comparison of Clinical and Hematological Parameters of Janus Kinase 2, Calreticulin or Myeloproliferative Leukemia Virus Oncogene Mutant Essential Thrombocythemia and Triple-Negative Essential Thrombocythemia. | YΔ±ldΔ±z J et al. | β | 2022 | β |
| Essential Thrombocythemia among Patients with Myeloproliferative Neoplasms in Haematology Unit of a Tertiary Care Centre: A Descriptive Cross-sectional Study. | Sah SK et al. | β | 2022 | β |
| Hydralazine Associated With Reduced Therapeutic Phlebotomy Frequency in a Nationwide Cohort Study: Real-World Effectiveness for Drug Repurposing. | Lin WZ et al. | β | 2022 | β |
| Polycythaemia Vera and Coronary Artery Bypass Graft Surgery: A Systematic Review of the Literature. | Janmohamed IK et al. | β | 2022 | β |
| Polycythemia Rubra Vera and Sporadic Bilateral Renal Angiomyolipomas: A Case Report. | Barton JC et al. | β | 2022 | β |
| Pulmonary Arterial Hypertension in Hospitalized Patients With Polycythemia VeraΒ (from the National Inpatient Database). | Stempel JM et al. | β | 2021 | β |
| Recent Advances in the Use of Molecular Analyses to Inform the Diagnosis and Prognosis of Patients with Polycythaemia Vera. | Stuckey R et al. | β | 2021 | β |
| Secondary polycythemia in chronic obstructive pulmonary disease: prevalence and risk factors. | Zhang J et al. | β | 2021 | β |
| Beyond Hemoglobin: When and How to Work Up Possible Polycythemia Vera. | Shaw G et al. | β | 2020 | β |
| Does Polycythemia Vera Increase Risk of Postoperative Complications Following Primary Total Joint Arthroplasty? A Retrospective Matched Control Cohort Study of 6932 Polycythemia Vera Patients. | Labaran LA et al. | β | 2020 | β |
| Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map. | Shallis RM et al. | β | 2020 | β |
| Investigation and management of erythrocytosis. | Mithoowani S et al. | β | 2020 | β |
| Oral Lichen Planus and Polycythemia: Possible Association. | Oueslati Y et al. | β | 2020 | β |
| Outcomes Following Posterior Lumbar Fusion in Patients with Polycythemia Vera. | Labaran LA et al. | β | 2020 | β |
| Prevalence Estimate of Blood Doping in Elite Track and Field Athletes During Two Major International Events. | Faiss R et al. | β | 2020 | β |
| The Essential Thrombocythemia in 2020: What We Know and Where We Still Have to Dig Deep. | Accurso V et al. | β | 2020 | β |
| Identification of significant geographic clustering of polycythemia vera cases in Montreal, Canada. | Le M et al. | β | 2019 | β |
| Essential thrombocythemia: a review of the clinical features, diagnostic challenges, and treatment modalities in the era of molecular discovery. | Chuzi S et al. | β | 2017 | β |
| Polycythemia causing posterior segment vascular occlusions. | Ganesan S et al. | β | 2017 | β |
| Comprehensive Gene expression meta-analysis and integrated bioinformatic approaches reveal shared signatures between thrombosis and myeloproliferative disorders. | Jha PK et al. | β | 2016 | β |
| Hormonal and Reproductive Factors and Risk of Myeloproliferative Neoplasms in Postmenopausal Women. | Leal AD et al. | β | 2016 | β |
| Identification of myeloproliferative neoplasm drug agents via predictive simulation modeling: assessing responsiveness with micro-environment derived cytokines. | Kobayashi SS et al. | β | 2016 | β |
| Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases. | Roskoski R | β | 2016 | β |
| Myeloid malignancies in the real-world: Occurrence, progression and survival in the UK's population-based Haematological Malignancy Research Network 2004-15. | Roman E et al. | β | 2016 | β |
| Risk of second primary malignancies in a population-based study of adult patients with essential thrombocythemia. | Shrestha R et al. | β | 2016 | β |
| Somatic JAK-2 V617F Mutational Analysis in Polycythemia Rubra Vera: a Tertiary Care Center Experience. | Sultan S et al. | β | 2016 | β |
| Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms. | Tapper W et al. | β | 2015 | β |
| [The impact of autophagy on proliferation of HEL cells and hematopoietic cells of polycythemia vera patients with JAK2 V617F mutation]. | Dong L et al. | β | 2015 | β |
| A 53-year-old woman with thrombocytosis and pulmonary embolism. | Demerouti E et al. | β | 2014 | β |
| Anthropometric, medical history and lifestyle risk factors for myeloproliferative neoplasms in the Iowa Women's Health Study cohort. | Leal AD et al. | β | 2014 | β |
| Application of the optimized CO-rebreathing method for determination of hemoglobin mass in patients with polycythemia vera. | Ahlgrim C et al. | β | 2014 | β |
| Epidemiology of myeloproliferative neoplasms in the United States. | Mehta J et al. | β | 2014 | β |
| How common are myeloproliferative neoplasms? A systematic review and meta-analysis. | Titmarsh GJ et al. | β | 2014 | β |
| Leukemic transformation in essential thrombocythemia. | Bhatt VR | β | 2014 | β |
| AKT is a therapeutic target in myeloproliferative neoplasms. | Khan I et al. | β | 2013 | β |
| Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors. | Choong ML et al. | β | 2013 | β |
| Efficacy and safety of cytoreductive therapies in patients with essential thrombocythaemia aged >80 years: an interim analysis of the EXELS study. | Kiladjian JJ et al. | β | 2013 | β |
| Essential thrombocythaemia: a single institution experience of 16Β years. | Varghese SJ et al. | β | 2013 | β |
| Heparin resistance and excessive thrombocytosis. | Koster A et al. | β | 2013 | β |
| Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. | Pascale S et al. | β | 2012 | β |
| Detectable clonal mosaicism from birth to old age and its relationship to cancer. | Laurie CC et al. | β | 2012 | β |
| Efficacious intermittent dosing of a novel JAK2 inhibitor in mouse models of polycythemia vera. | Kraus M et al. | β | 2012 | β |
| Hematologic malignancies: an opportunity to fill a gap in cancer surveillance. | Penberthy L et al. | β | 2012 | β |
| Local and global returns from research in stem cells: the case of the California Institute for Regenerative Medicine. | Alberro J | β | 2012 | β |
| The small molecule inhibitor G6 significantly reduces bone marrow fibrosis and the mutant burden in a mouse model of Jak2-mediated myelofibrosis. | Kirabo A et al. | β | 2012 | β |
| Why does my patient have thrombocytosis? | Sulai NH et al. | β | 2012 | β |
| Prevalence of blood doping in samples collected from elite track and field athletes. | Sottas PE et al. | β | 2011 | β |
| Pulsatile tinnitus as a first symptom of essential thrombocythemia. | Okazaki H et al. | β | 2011 | β |
| Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis. | Koppikar P et al. | β | 2010 | β |
| The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy. | Dragani A et al. | β | 2010 | β |
| Jakking up tumor registry reporting of the myeloproliferative neoplasms. | Selinger HA et al. | β | 2009 | β |
| [Retrospective analysis of the efficacy and tolerability of anagrelide in patients with essential thrombocytemia: Spanish registry of essential thrombocytemia]. | Giralt M et al. | β | 2009 | β |
| Use of molecular testing to identify a cluster of patients with polycythemia vera in eastern Pennsylvania. | Seaman V et al. | β | 2009 | β |
| Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. | Rollison DE et al. | β | 2008 | β |